

14<sup>th</sup> Congress of the European Hematology Association  
Satellite Symposium

# Improving Clinical Outcomes in CML: A Changing Therapeutic Landscape

Thursday, 4 June 2009

16.15 – 18.15

Hall 3

Internationales Congress  
Centrum (ICC)  
Berlin, Germany



 **NOVARTIS**  
ONCOLOGY



# Improving Clinical Outcomes in CML: A Changing Therapeutic Landscape

## Agenda and Faculty

Chair: Gianantonio Rosti, MD

16:15 **Pattern of Practice Question**

16:20 **Efficacy of second generation TKIs as second line therapy for CML**

Oliver G. Ottmann, MD  
Johann Wolfgang Goethe University  
Frankfurt, Germany

16:40 **Pattern of Practice Question**

16:45 **BCR-ABL kinase domain mutational analysis: Biology of imatinib resistance**

Simona Soverini, PhD  
University of Bologna  
Bologna, Italy

17:00 **Pattern of Practice Question**

17:05 **Clinical relevance of BCR-ABL mutations**

Pierre Laneuville, MD  
McGill University  
Montreal, Quebec, Canada

17:20 **Interactive Clinical Case:**

**Second line therapy for chronic phase CML: How should clinicians choose the best option?**

Francis J. Giles, MD  
University of Texas,  
San Antonio, Texas, United States

17:45 **Pattern of Practice Question**

17:50 **Newly diagnosed CML: Can we improve upon results achieved with imatinib?**

Gianantonio Rosti, MD  
University of Bologna  
Bologna, Italy

18:10 **Closing Remarks**

18:15 **Adjourn**